Literature DB >> 21875763

Ruthenium(II) phosphine/diimine/picolinate complexes: inorganic compounds as agents against tuberculosis.

Fernando R Pavan1, Gustavo V Poelhsitz, Marilia I F Barbosa, Sergio R A Leite, Alzir A Batista, Javier Ellena, Leticia S Sato, Scott G Franzblau, Virtudes Moreno, Dinorah Gambino, Clarice Q F Leite.   

Abstract

This paper describes the synthesis and characterization of four new ruthenium complexes containing 1,4 bis(diphenylphosphino)butane (dppb), 2-pyridinecarboxylic acid anion (pic) and the diimines [(2,2'-bipyridine (bipy), 4,4'-dimethyl-2,2'-bipyridine (Me-bipy), 4,4'-dichloro-2,2'-bipyridine (Cl-bipy) and 1,10-phenanthroline (phen) as ligands, with formulae [Ru(pic)(dppb)(bipy)]PF(6) (SCAR01), [Ru(pic)(dppb)(Me-bipy)]PF(6) (SCAR02), [Ru(pic)(dppb)(Cl-bipy)]PF(6) (SCAR03) and [Ru(pic)(dppb)(phen)]PF(6) (SCAR04). Additionally, the in vitro anti-Mycobacterium tuberculosis (MTB) activity, cytotoxicity and activity against in vitro infection of these complexes and two more complexes, cis-[Ru(pic)(dppe)(2)]PF(6) (SCAR05) and cis-[RuCl(2)(dppb)(bipy)] (SCAR06), and their free ligands are described and discussed. All compounds showed excellent MIC against MTB, low cytotoxicity and a selectivity index higher than 10. Also, all compounds showed significant intracellular inhibition and the compound SCAR05 showed a better activity than rifampin and SQ109. This is the first report of activity against in vitro infection of ruthenium compounds.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21875763     DOI： 10.1016/j.ejmech.2011.08.023

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN： 0223-5234            Impact factor:   6.514


  11 in total

1.  Transition metal-α-amino acid complexes with antibiotic activity against Mycobacterium spp.

Authors:  George W Karpin; Joseph S Merola; Joseph O Falkinham
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

2.  Nitro/nitrosyl-ruthenium complexes are potent and selective anti-Trypanosoma cruzi agents causing autophagy and necrotic parasite death.

Authors:  Tanira M Bastos; Marília I F Barbosa; Monize M da Silva; José W da C Júnior; Cássio S Meira; Elisalva T Guimaraes; Javier Ellena; Diogo R M Moreira; Alzir A Batista; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

3.  Cytoxicity and apoptotic mechanism of ruthenium(II) amino acid complexes in sarcoma-180 tumor cells.

Authors:  Aliny Pereira Lima; Flávia Castro Pereira; Marcio Aurelio Pinheiro Almeida; Francyelli Mariana Santos Mello; Wanessa Carvalho Pires; Thallita Monteiro Pinto; Flávia Karina Delella; Sérgio Luis Felisbino; Virtudes Moreno; Alzir Azevedo Batista; Elisângela de Paula Silveira-Lacerda
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

4.  Antioxidant enzyme inhibitor role of phosphine metal complexes in lung and leukemia cell lines.

Authors:  Burcu Saygıdeğer Demir; Tuğba Keleş; Osman Serindağ
Journal:  Bioinorg Chem Appl       Date:  2014-12-28       Impact factor: 7.778

5.  Neutron activation increases activity of ruthenium-based complexes and induces cell death in glioma cells independent of p53 tumor suppressor gene.

Authors:  Aline Monezi Montel; Raquel Gouvêa Dos Santos; Pryscila Rodrigues da Costa; Elisângela de Paula Silveira-Lacerda; Alzir Azevedo Batista; Wagner Gouvêa Dos Santos
Journal:  Biometals       Date:  2017-03-03       Impact factor: 2.949

6.  Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis.

Authors:  Mariana R Sato; João A Oshiro Junior; Rachel Ta Machado; Paula C de Souza; Débora L Campos; Fernando R Pavan; Patricia B da Silva; Marlus Chorilli
Journal:  Drug Des Devel Ther       Date:  2017-03-20       Impact factor: 4.162

7.  Combatting AMR: photoactivatable ruthenium(ii)-isoniazid complex exhibits rapid selective antimycobacterial activity.

Authors:  Nichola A Smith; Pingyu Zhang; Simon E Greenough; Michael D Horbury; Guy J Clarkson; Daniel McFeely; Abraha Habtemariam; Luca Salassa; Vasilios G Stavros; Christopher G Dowson; Peter J Sadler
Journal:  Chem Sci       Date:  2016-08-30       Impact factor: 9.825

8.  A Nanostructured Lipid System to Improve the Oral Bioavailability of Ruthenium(II) Complexes for the Treatment of Infections Caused by Mycobacterium tuberculosis.

Authors:  Patricia B da Silva; Eduardo Sinésio de Freitas; Mariana Cristina Solcia; Paula Carolina de Souza; Monize Martins da Silva; Alzir Azevedo Batista; Carlos E Eismann; Ana Marta C M Rolisola; Amauri A Menegário; Rosilene Fressatti Cardoso; Marlus Chorilli; Fernando R Pavan
Journal:  Front Microbiol       Date:  2018-12-06       Impact factor: 5.640

9.  In vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosis.

Authors:  Fernando R Pavan; Gustavo V Poelhsitz; Lucas V P da Cunha; Marilia I F Barbosa; Sergio R A Leite; Alzir A Batista; Sang H Cho; Scott G Franzblau; Mariana S de Camargo; Flávia A Resende; Eliana A Varanda; Clarice Q F Leite
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

Review 10.  Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in Mycobacterium tuberculosis?

Authors:  Bruno L Abbadi; Valnês da Silva Rodrigues-Junior; Adilio da Silva Dadda; Kenia Pissinate; Anne D Villela; Maria M Campos; Luiz G de França Lopes; Cristiano V Bizarro; Pablo Machado; Eduardo H S Sousa; Luiz A Basso
Journal:  Front Microbiol       Date:  2018-05-01       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.